文献速递神经肿瘤

复发高级别胶质瘤再程放疗前18F-FET PET动态达峰时间分析与早期静态叠加图像的额外预后价值

18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?
PubMed 文献 · J Neurooncol · 2017-01-19

该回顾性研究纳入72例复发高级别胶质瘤患者,在再程放疗前进行18F-FET PET检查,评估动态达峰时间分析和早期静态叠加图像的预后价值。结果显示TTPmin较短与再程放疗后更短的总生存相关,TTPmin<12.5分钟为6个月,12.5-25分钟为7个月,>25分钟为11个月(p=0.027)。TTPmin在多因素分析中也是独立预后因素(p=0.011)。早期TBRmax及其他常规PET参数与生存无显著相关。

要点

  • TTPmin<12.5分钟、12.5-25分钟和>25分钟患者再程放疗后生存分别为6、7和11个月(p=0.027)。
  • TTPmin在多因素分析中与生存显著相关(p=0.011),TACs模式和KPS也与生存相关。
  • 早期TBRmax及其他常规PET参数与生存无显著相关。

核心结论

  • 动态18F-FET PET的TTPmin对复发高级别胶质瘤再程放疗前具有较高预后价值,而早期TBRmax无预后价值。

研究设计与样本

  • 回顾性分析72例复发高级别胶质瘤患者,再程放疗前接受18F-FET PET检查,评估TTPmin、早期TBRmax等参数与再程放疗后生存的关系。

主要发现

  • TTPmin<12.5分钟、12.5-25分钟和>25分钟患者再程放疗后生存分别为6、7和11个月(p=0.027)。
  • TTPmin在单因素(p=0.027;连续变量)和多因素分析(p=0.011;连续变量)中均与生存显著相关。
  • 多因素分析中,TACs模式(递增 vs 递减,p=0.008)和KPS(<70 vs ≥70,p=0.015)也与生存显著相关。
  • 早期TBRmax及其他常规PET参数在单因素分析中与生存无显著相关。

临床怎么用

  • 作者认为,使用TTPmin的动态18F-FET PET可能通过体素级TTPmin分析用于剂量绘画和PET引导的剂量递增,从而在未来帮助个体化再程放疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most high-grade gliomas (HGG) recur after initial multimodal therapy and re-irradiation (Re-RT) has been shown to be a valuable re-treatment option in selected patients. We evaluated the prognostic value of dynamic time-to-peak analysis and early static summation images in O-(2-18F-fluoroethyl)-l-tyrosine (18F-FET) PET for patients treated with Re-RT ± concomitant bevacizumab. We retrospectively analyzed 72 patients suffering from recurrent HGG with 18F-FET PET prior to Re-RT. PET analysis revealed the maximal tumor-to-background-ratio (TBRmax), the biological tumor volume, the number of PET-foci and pattern of time-activity-curves (TACs; increasing vs. decreasing). Furthermore, the novel PET parameters early TBRmax (at 5-15 min post-injection) and minimal time-to-peak (TTPmin) were evaluated. Additional analysis was performed for gender, age, KPS, O6-methylguanine-DNA methyltransferase methylation status, isocitrate dehydrogenase 1 mutational status, WHO grade and concomitant bevacizumab therapy. The influence of PET and clinical parameters on post-recurrence survival (PRS) was investigated. Shorter TTPmin was related to shorter PRS after Re-RT with 6 months for TTPmin < 12.5 min, 7 months for TTPmin 12.5-25 min and 11 months for TTPmin >25 min (p = 0.027). TTPmin had a significant impact on PRS both on univariate (p = 0.027; continuous) and multivariate analysis (p = 0.011; continuous). Other factors significantly related to PRS on multivariate analysis were increasing vs. decreasing TACs (p = 0.008) and Karnofsky Performance Score (p = 0.015; <70 vs. ≥70). Early TBRmax as well as the other conventional PET parameters were not significantly related to PRS on univariate analysis. Dynamic 18F-FET PET with TTPmin provides a high prognostic value for recurrent HGG prior to Re-RT, whereas early TBRmax does not. Dynamic 18F-FET PET using TTPmin might help to personalize Re-RT treatment regimens in future through voxelwise TTPmin analysis for dose painting purposes and PET-guided dose escalation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fleischmann DF, Unterrainer M, Bartenstein P, et al. 18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images? J Neurooncol. 2017. PMID: 28102485. doi:10.1007/s11060-016-2366-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。